

Antimicrobial Drugs: A Lifeline against Infectious Diseases

Stephen De Silva*

Department of Medicine Use and Safety, Monash University, Melbourne, Australia

Abstract

Antimicrobial drugs, including fluoroquinolones: Antibiotics are used to treat bacterial infections. They can be further classified into several categories, such as penicillin, cephalosporin, macrolides, tetracycline and fluoroquinolones. Each category has a unique mode of action and targets specific bacteria or bacterial components. Inhibition of cell wall synthesis: Many antibiotics, such as penicillin and cephalosporin, interfere with the synthesis of bacterial cell walls. By disrupting this essential structure, the drugs weaken the bacteria, making them more susceptible to destruction by the immune system. Inhibition of protein synthesis: Certain antibiotics, like macrolides and tetracycline, inhibit bacterial protein synthesis. By blocking the production of vital bacterial proteins, these drugs impede bacterial growth and reproduction. Inhibition of nucleic acid synthesis: Antimicrobial drugs, including fluoroquinolones, interfere with the synthesis of bacterial DNA or RNA. This disruption prevents bacteria from multiplying and spreading, aiding in the eradication of the infection.

Keywords: Drugs • Fluoroquinolones • Mechanism

Introduction

In the constant battle against infectious diseases, antimicrobial drugs have emerged as a vital weapon, saving countless lives worldwide. These drugs, also known as antibiotics, antivirals and antifungals, are substances specifically designed to inhibit or kill microorganisms that cause infections. Over the years, antimicrobial drugs have revolutionized the field of medicine, significantly reducing the morbidity and mortality associated with bacterial, viral and fungal infections. This article explores the importance of antimicrobial drugs, their classification, mechanisms of action, challenges associated with their use and the future outlook for combating antimicrobial resistance. Antimicrobial drugs play a crucial role in the treatment and prevention of infectious diseases. They have transformed modern medicine by providing effective therapeutic options to combat bacterial, viral and fungal infections. These drugs have been instrumental in treating common infections like urinary tract infections, respiratory tract infections, skin infections and sexually transmitted diseases. Additionally, they have played a pivotal role in preventing infections during surgeries, childbirth and immune compromised conditions.

Literature Review

These adverse effects can vary depending on the specific drug and the individual's response. Limited drug options: Some infections may become challenging to treat due to limited drug options. The development of new antimicrobial drugs has slowed down in recent years, leaving healthcare providers with fewer alternatives for certain drug-resistant infections. Antibiotics are used to treat bacterial infections. They can be further classified into several categories, such as penicillin, cephalosporin, macrolides, tetracycline and fluoroquinolones. Each category has a unique mode of action and targets specific bacteria or bacterial components. By blocking the production of vital bacterial proteins, these drugs impede bacterial growth and reproduction. Antimicrobial drugs, including fluoroquinolones, interfere with the synthesis of bacterial DNA

or RNA. This disruption prevents bacteria from multiplying and spreading, aiding in the eradication of the infection. Antiviral drugs target specific steps in the viral replication process. For example, some antivirals block viral enzymes required for replication, while others inhibit viral entry into host cells. This disruption prevents bacteria from multiplying and spreading, aiding in the eradication of the infection [1].

Antiviral drugs target specific steps in the viral replication process. For example, some antivirals block viral enzymes required for replication, while others inhibit viral entry into host cells. Access to antimicrobial drugs remains a challenge, particularly in low-income countries. The cost of these medications, coupled with limited healthcare infrastructure, hampers the ability to provide optimal treatment to those in need. To combat the challenges associated with antimicrobial drug use, responsible antimicrobial stewardship practices are crucial. These practices involve optimizing the use of antimicrobial drugs to preserve their effectiveness. They can work by blocking viral entry, inhibiting viral DNA or RNA synthesis, or preventing viral particle assembly and release. Antifungals target various aspects of fungal cell physiology, including cell wall synthesis, membrane integrity, or disruption of metabolic processes essential for fungal growth [2].

Discussion

Antimicrobial drugs are classified into different categories based on their target microorganisms. Antibiotics specifically target bacteria, while antivirals combat viral infections and antifungals are designed to treat fungal infections. Within each category, there are different classes of drugs with distinct mechanisms of action. Antibiotics can be categorized into several classes such as penicillin, cephalosporin, macrolides and fluoroquinolones. These drugs work by inhibiting bacterial cell wall synthesis, protein synthesis, DNA replication, or interfering with metabolic pathways, ultimately leading to bacterial death or growth inhibition. Antivirals are designed to specifically target viral replication and are used to treat viral infections like influenza, HIV and herpes. One of the most pressing challenges is the development of antimicrobial resistance. Overuse and misuse of these drugs have led to the emergence of resistant strains of bacteria, fungi, parasites and viruses. This renders certain antimicrobial drugs ineffective, making infections more difficult to treat and potentially causing higher mortality rates. Like any medication, antimicrobial drugs can have side effects. Common side effects include gastrointestinal disturbances, allergic reactions and organ toxicity. The widespread use and misuse of antimicrobial drugs have contributed to the rise of Antimicrobial Resistance (AMR), one of the most significant global health threats. AMR occurs when microorganisms develop mechanisms to survive the effects of antimicrobial drugs, rendering them ineffective. This phenomenon not only limits treatment options but also increases healthcare costs and mortality rates. To combat AMR, it is crucial to promote responsible use of antimicrobial drugs [3,4].

***Address for Correspondence:** Stephen De Silva, Department of Medicine Use and Safety, Monash University, Melbourne, Australia; E-mail: desilva32@gmail.com

Copyright: © 2023 Silva SD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 02 February 2023, Manuscript No. Antimicro-23-102516; **Editor assigned:** 04 February 2023, PreQC No. P-102516; **Reviewed:** 16 February 2023, QC No. Q-102516; **Revised:** 21 February 2023, Manuscript No. R-102516; **Published:** 28 February 2023, DOI: 10.37421/2472-1212.2023.9.295

This includes appropriate prescription practices, adherence to treatment regimens and public education regarding the proper use of these drugs. Additionally, the development of new antimicrobial drugs and alternative treatment strategies is imperative. The future of antimicrobial drug development lies in innovative approaches such as combination therapies, drug repurposing and the discovery of novel targets. Combination therapies involving multiple drugs with different mechanisms of action can enhance treatment efficacy while minimizing the development of resistance. Drug repurposing, which involves identifying new therapeutic uses for existing drugs, offers a cost-effective strategy to combat AMR. Furthermore, on-going research in the field of immunotherapy and phage therapy shows promise in harnessing the body's immune system or utilizing bacteriophages to combat infections [5,6].

Conclusion

Antimicrobial drugs have been a lifeline in the fight against infectious diseases. They have revolutionized medicine, saving countless lives and alleviating suffering. However, the emergence of antimicrobial resistance poses a significant challenge that requires global attention and collaborative efforts. By promoting responsible use of these drugs, investing in research and development and adopting innovative strategies, we can continue to harness the power of antimicrobial drugs and safeguard public health. It is crucial that we take action now to ensure a future where these lifesaving drugs remain effective against infectious diseases.

Acknowledgement

None.

Conflict of Interest

No potential conflict of interest was reported by the authors.

References

1. Karri, Veera Venkata Satyanarayana Reddy, Gowthamarajan Kuppusamy, Siddhartha Venkata Talluri and Karthik Yamjala, et al. "Current and emerging therapies in the management of diabetic foot ulcers." *Curr Med Res Opin* (2016): 519-542.
2. Bramer, Wicher and Paul Bain. "Updating search strategies for systematic reviews using EndNote." *J Med Libr Assoc: JMLA* 105 (2017): 285.
3. Olid, Anna Selva, Ivan Solà, Leticia A. Barajas-Navà and Oscar D. Gianneo, et al. "Systemic antibiotics for treating diabetic foot infections." *Cochrane Database Syst Rev* 9 (2015).
4. Tchero, Huidi, Pauline Kangambega, Lazarre Noubou and Beatrice Becsangeli, et al. "Antibiotic therapy of diabetic foot infections: A systematic review of randomized controlled trials." *Wound Repair Regen* 26 (2018): 381-391.
5. Tardáguila-García, Aroa, Irene Sanz-Corbalán, Josep M. García-Alamino and Raju Ahluwalia, et al. "Medical vs. surgical treatment for the management of diabetic foot osteomyelitis: A systematic review." *J Clin Med* 10 (2021): 1237.
6. Tan, Chee Wei and Maciej Piotr Chlebicki. "Urinary tract infections in adults." *Singap Med* 57 (2016): 485.

How to cite this article: Silva, Stephen De. "Antimicrobial Drugs: A Lifeline against Infectious Diseases." *J Antimicrob Agents* 9 (2023): 295.